Effectiveness of nirmatrelvir/ritonavir and molnupiravir in non-hospitalized adults with COVID-19: systematic review and meta-analysis of observational studies
Journal of Antimicrobial Chemotherapy · 03.09.2024 · 79 (9) · 2119-2131
DOI: 10.1093/jac/dkae163 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Journal of Antimicrobial Chemotherapy, online erschienen am 31.05.2024. Verfasst von Yonatan M Mesfin und 5 weiteren Autor:innen. Beteiligte Einrichtung: School of Public Health, LKS Faculty of Medicine, World Health Organization Collaborating Centre for Infectious Disease Epidemiology and Control, The…. Hauptthemen laut MEDLINE: Antiviral Agents, COVID-19 Drug Treatment, Cytidine, Hydroxylamines. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Collaborative Research Fund, Health and Medical Research Fund, Innovation and Technology Commission.
Abstract (Originalsprache)
Objective
To determine the effectiveness of nirmatrelvir/ritonavir and molnupiravir among vaccinated and unvaccinated non-hospitalized adults with COVID-19.
Methods
Observational studies of nirmatrelvir/ritonavir or molnupiravir compared to no antiviral drug treatment for COVID-19 in non-hospitalized adults with data on vaccination status were included. We searched MEDLINE, EMBASE, Scopus, Web of Science, WHO COVID-19 Research Database and medRxiv for reports published between 1 January 2022 and 8 November 2023. The primary outcome was a composite of hospitalization or mortality up to 35 days after COVID-19 diagnosis. Risk of bias was assessed with ROBINS-I. Risk ratios (RR), hazard ratios (HR) and risk differences (RD) were separately estimated using random-effects models.
Results
We included 30 cohort studies on adults treated with nirmatrelvir/ritonavir (n = 462 279) and molnupiravir (n = 48 008). Nirmatrelvir/ritonavir probably reduced the composite outcome (RR 0.62, 95%CI 0.55–0.70; I2 = 0%; moderate certainty) with no evidence of effect modification by vaccination status (RR Psubgroup = 0.47). In five studies, RD estimates against the composite outcome for nirmatrelvir/ritonavir were 1.21% (95%CI 0.57% to 1.84%) in vaccinated and 1.72% (95%CI 0.59% to 2.85%) in unvaccinated subgroups. Molnupiravir may slightly reduce the composite outcome (RR 0.75, 95%CI 0.67–0.85; I2 = 32%; low certainty). Evidence of effect modification by vaccination status was inconsistent among studies reporting different effect measures (RR Psubgroup = 0.78; HR Psubgroup = 0.08). In two studies, RD against the composite outcome for molnupiravir were −0.01% (95%CI −1.13% to 1.10%) in vaccinated and 1.73% (95%CI −2.08% to 5.53%) in unvaccinated subgroups.
Conclusions
Among cohort studies of non-hospitalized adults with COVID-19, nirmatrelvir/ritonavir is effective against the composite outcome of severe COVID-19 independent of vaccination status. Further research and a reassessment of molnupiravir use among vaccinated adults are warranted. Registration PROSPERO CRD42023429232.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- School of Public Health, LKS Faculty of Medicine, World Health Organization Collaborating Centre for Infectious Disease Epidemiology and Control, The University of Hong Kong, Hong Kong Special Administration Region, Hon…
- Immunity & Global Health, Murdoch Children's Research Institute (MCRI), Parkville, VIC, Australia.
- Laboratory of Data Discovery for Health (D24H), Hong Kong Science and Technology Park, New Territories, Hong Kong Special Administration Region, Hong Kong, China.
- Centre for Safe Medication Practice and Research, Department of Pharmacology and Pharmacy, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong Special Administration Region, Hong Kong, China.
- Global Centre for Preventive Health and Nutrition, Deakin University, Geelong, VIC, Australia.
- Institute for Physical Activity and Nutrition, Deakin University, Geelong, VIC, Australia.
ORCID-Profile: Yonatan M Mesfin, Joseph E Blais, Kelemu Tilahun Kibret, Teketo Kassaw Tegegne, Benjamin J Cowling, Peng Wu
Förderung
- Collaborative Research Fund
- Health and Medical Research Fund
- Innovation and Technology Commission
- Deakin University
Zitieren
APA
Mesfin, Y. M., Blais, J. E., Kibret, K. T., Tegegne, T. K., Cowling, B. J., & Wu, P. (2024). Effectiveness of nirmatrelvir/ritonavir and molnupiravir in non-hospitalized adults with COVID-19: systematic review and meta-analysis of observational studies. Journal of Antimicrobial Chemotherapy, 79(9), 2119-2131. https://doi.org/10.1093/jac/dkae163
Vancouver
Mesfin YM, Blais JE, Kibret KT, Tegegne TK, Cowling BJ, Wu P. Effectiveness of nirmatrelvir/ritonavir and molnupiravir in non-hospitalized adults with COVID-19: systematic review and meta-analysis of observational studies. Journal of Antimicrobial Chemotherapy. 2024;79(9):2119-2131. doi:10.1093/jac/dkae163
BibTeX
@article{Mesfin2024,
author = {Mesfin, Yonatan M and Blais, Joseph E and Kibret, Kelemu Tilahun and Tegegne, Teketo Kassaw and Cowling, Benjamin J and Wu, Peng},
title = {Effectiveness of nirmatrelvir/ritonavir and molnupiravir in non-hospitalized adults with COVID-19: systematic review and meta-analysis of observational studies},
journal = {Journal of Antimicrobial Chemotherapy},
year = {2024},
volume = {79},
number = {9},
pages = {2119--2131},
doi = {10.1093/jac/dkae163}
}
EUVIMED